J&J to Acquire Abiomed for US$16.6 B
By Ayush Saxena
Pharma Deals Review: Vol 2022 Issue 11 (Table of Contents)
Published: 11 Nov-2022
DOI: 10.3833/pdr.v2022.i11.2747 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In an attempt to strengthen its medical device division, Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Abiomed for an upfront payment of US$380 per share, representing a total deal value of US$16...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS